The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells

Phosphorylation of receptor tyrosine kinases (RTKs) has a key role in cellular functions contributing to the malignant phenotype of tumor cells. We and others have previously demonstrated that RTK ROR1 is overexpressed in chronic lymphocytic leukemia (CLL). Silencing siRNA downregulated ROR1 and induced apoptosis of CLL cells. In the present study we analysed ROR1 isoforms and the phosphorylation pattern in CLL cells (n=38) applying western blot and flow-cytometry using anti-ROR1 antibodies and an anti-phospho-ROR1 antibody against the TK domain. Two major ROR1 bands with the size of 105 and 130 kDa respectively were identified, presumably representing unglycosylated (immature) and glycosylated (mature) ROR1 respectively as well as a 260 kDa band which may represent dimerized ROR1. A ROR1 band of 64 kDa that may correspond to a C-terminal fragment was also noted, present only in the nucleus. The 105 kDa ROR1 isoform was more frequently expressed in non-progressive as compared to progressive CLL patients (p=0.03). The 64, 105, 130 and 260 kDa bands were constitutively phosphorylated both at tyrosine and serine residues. Phosphorylation intensity of the mature (130 kDa) isoform was significantly higher in progressive than in non-progressive disease (p<0.001). Incubation of CLL cells with a mouse anti-ROR1 KNG or an anti-ROR1 CRD mAb respectively induced dephosphorylation of ROR1 before entering apoptosis. In conclusion CLL cells expressed different isoforms of ROR1 which were constitutively phosphorylated. The mature, phosphorylated ROR1 isoform was associated with a progressive disease stage. Targeting ROR1 by mAbs induced specific dephosphorylation and leukemic cell death. ROR1 might be an interesting therapeutic target.

[1]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[2]  M. Jeddi-Tehrani,et al.  Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells , 2012, Leukemia.

[3]  Edward L. Huttlin,et al.  A Tissue-Specific Atlas of Mouse Protein Phosphorylation and Expression , 2010, Cell.

[4]  J. Marth,et al.  Mammalian glycosylation in immunity , 2008, Nature reviews. Immunology.

[5]  S. Razavi,et al.  Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia , 2009, Leukemia & lymphoma.

[6]  Stefan Mundlos,et al.  Modulation of GDF5/BRI‐b signalling through interaction with the tyrosine kinase receptor Ror2 , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[7]  Hideki Yamamoto,et al.  Wnt 5 a regulates distinct signaling pathways by binding to Frizzled 2 , 2009 .

[8]  M. Hu,et al.  Bone Microenvironment and Androgen Status Modulate Subcellular Localization of ErbB3 in Prostate Cancer Cells , 2007, Molecular Cancer Research.

[9]  S. Sadekova,et al.  Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor , 2001, Oncogene.

[10]  Pierre Hubert,et al.  Tyrosine kinase receptors as attractive targets of cancer therapy. , 2004, Critical reviews in oncology/hematology.

[11]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[12]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[13]  Joseph Schlessinger,et al.  Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases , 2010, Molecules and cells.

[14]  A. Harris,et al.  The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non‐neoplastic lymphadenopathy: an immunohistochemical study , 2005, Histopathology.

[15]  L. Rassenti,et al.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a , 2008, Proceedings of the National Academy of Sciences.

[16]  S. Razavi,et al.  Fc receptor‐like 1–5 molecules are similarly expressed in progressive and indolent clinical subtypes of B‐cell chronic lymphocytic leukemia , 2008, International journal of cancer.

[17]  L. Johnson.  The regulation of protein phosphorylation. , 2009, Biochemical Society transactions.

[18]  M. Hung,et al.  Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor , 2005, Molecular and Cellular Biology.

[19]  M. Bayık,et al.  Aberrant expression of c‐met and HGF/c‐met pathway provides survival advantage in B‐chronic lymphocytic leukemia , 2011, Cytometry. Part B, Clinical cytometry.

[20]  Adam Cole,et al.  Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. , 2004, The Biochemical journal.

[21]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[22]  Yan Liu,et al.  Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase , 2008, Journal of cellular biochemistry.

[23]  N. Hooper,et al.  ADAMs family members as amyloid precursor protein α‐secretases , 2003 .

[24]  Yan Liu,et al.  Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-3(beta) phosphorylation and promotes osteoblast differentiation and bone formation. , 2007, Molecular endocrinology.

[25]  Frank E. Jones,et al.  The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone , 2004, The Journal of cell biology.

[26]  N. Hooper,et al.  ADAMs family members as amyloid precursor protein alpha-secretases. , 2003, Journal of neuroscience research.

[27]  G. Widhopf,et al.  ROR1 Expression Accelerates Leukemia Development in RORxTCL1 Transgenic Mice , 2011 .

[28]  J. Wang-Rodriguez,et al.  ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth , 2012, PloS one.

[29]  P. Lyu,et al.  Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyrosine kinase ROR1. , 2011, Anticancer research.

[30]  A. Kozubík,et al.  Post‐translational modifications regulate signalling by Ror1 , 2011, Acta physiologica.

[31]  P. Masiakowski,et al.  A novel family of cell surface receptors with tyrosine kinase-like domain. , 1992, The Journal of biological chemistry.

[32]  C. Larsson,et al.  Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy , 2008, International journal of cancer.

[33]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[34]  R. Wynn,et al.  Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells , 2006, Cancer biology & therapy.

[35]  R. Fourney,et al.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.

[36]  A. Porwit,et al.  Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies , 2013, Leukemia & lymphoma.

[37]  D. Pleasure,et al.  Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. , 1996, Oncogene.

[38]  S. Merat,et al.  Expansion of CD4+ CD25+ FoxP3+ regulatory T cells in chronic hepatitis C virus infection. , 2010, Iranian journal of immunology : IJI.

[39]  J. Hussain,et al.  CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. , 2008, Molecular cell.

[40]  P. Lyu,et al.  Nuclear localization of orphan receptor protein kinase (Ror1) is mediated through the juxtamembrane domain , 2010, BMC Cell Biology.

[41]  Y. Minami,et al.  Ror‐family receptor tyrosine kinases in noncanonical Wnt signaling: Their implications in developmental morphogenesis and human diseases , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

[42]  Adrian Wiestner,et al.  Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia , 2008, Clinical Cancer Research.

[43]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[44]  Hideki Yamamoto,et al.  Wnt5a regulates distinct signalling pathways by binding to Frizzled2 , 2010, The EMBO journal.

[45]  M. Hung,et al.  Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family* , 2007, Journal of Biological Chemistry.

[46]  S. Paganoni,et al.  Expression and subcellular localization of Ror tyrosine kinase receptors are developmentally regulated in cultured hippocampal neurons , 2003, Journal of neuroscience research.

[47]  M. Jeddi-Tehrani,et al.  Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells , 2013, PloS one.

[48]  L. Trusolino,et al.  ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis , 2011, BMC Proceedings.

[49]  A. Ross,et al.  Catalysis of serine and tyrosine autophosphorylation by the human insulin receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.